The Pharma Letter | Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy ... The Pharma Letter It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries' Treanda, Mundipharma's Ribomustin/Levact, Symbio Pharmaceuticals/Eisai's Treakisym) in combination with rituximab, ... |
